Оджаара (Ojjaara, Momelotinib) 100 мг 30 таб , Generic

Ojjaara, containing the active substance momelotinib, is a medicine for the treatment of adult patients with myelofibrosis accompanied by anemia. This rare oncological disease of the blood is characterized by scarring of the bone marrow, which prevents normal blood formation. The pharmacological action of the medicine is based on the blocking of specific enzymes JAK1, JAK2 and its mutated form, which are involved in the regulation of blood cell production and inflammatory processes. Ojjaara, approved by the FDA on September 15, 2023, belongs to the class of multikinase inhibitors and is not a chemotherapy agent. The mechanism of action is directed at the JAK-STAT signaling pathway, the disruption of which is associated with the development of various forms of leukemia, lymphomas and myeloproliferative pathologies.